August 29, 2019
Mitsubishi Tanabe Pharma said on August 28 that its Israeli subsidiary NeuroDerm has launched a US PIII clinical study of ND0612, a continuous subcutaneous liquid formulation of levodopa/carbidopa, in patients with Parkinson’s disease (PD). With the agent, the Japanese company...read more